New drug shows promise for Tough-to-Treat blood cancers
NCT ID NCT05526313
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called Purinostat Mesylate in 29 people with relapsed or refractory B-cell lymphomas, a type of blood cancer. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Researchers hope this drug could offer a new option for patients who have run out of standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Purinostat Mesylate
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat B-cell lymphomas.
- What could go wrong
- This is a very early Phase 1 trial with only 29 participants, so safety and dosing are still being figured out. It may not lead to an effective treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a Two-Drug combo keep aggressive lymphoma at bay?